Schrodinger SDGR Drug discovery — Deferred Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Schrodinger in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Schrodinger's drug discovery — deferred revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Schrodinger's drug discovery — deferred revenue?
- Schrodinger (SDGR) reported drug discovery — deferred revenue of $42.36M in Q1 2026.
- How has Schrodinger's drug discovery — deferred revenue changed year-over-year?
- Schrodinger's drug discovery — deferred revenue decreased by 5.6% year-over-year, from $44.87M to $42.36M.
- What does drug discovery — deferred revenue mean?
- This is the liability representing payments received from customers for services that have not yet been performed or delivered. It serves as a measure of future revenue that is already contracted but not yet recognized on the income statement.